Research
William Blair Initiates Enliven Therapeutics at Outperform
Enliven Therapeutics (ELVN) has an average rating of buy and mean price target of $73.45, according to analysts polled by FactSet.
$ELVN
$ELVN
10 stories mentioning ELVNUpdated 26d ago
Every FINWIRES story that references ELVN, newest first.
What are analysts saying about ELVN?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on ELVN?
Research
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target
Enliven Therapeutics (ELVN) has an average rating of buy and mean price target of $73.45, according to analysts polled by FactSet.
$ELVN
Insider Trading
Enliven Therapeutics Insider Sold Shares Worth $263,373, According to a Recent SEC Filing
Helen Louise Collins, Chief Medical Officer, on July 17, 2026, sold 5,000 shares in Enliven Therapeutics (ELVN) for $263,373. Following the Form 4 filing with the SEC, Collins has control over a total of 25,000 common shares of the company, with 25,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1672619/000170124726000011/xslF345X05/form4-07212026_090758.xml
$ELVN
Insider Trading
Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing
Benjamin Hohl, CFO, on July 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $316,780. Following the Form 4 filing with the SEC, Hohl has control over a total of 46,054 common shares of the company, with 46,054 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1672619/000188276426000006/xslF345X05/form4-07212026_090724.xml
$ELVN
Insider Trading
Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing
Lori Anne Kunkel, Director, on July 06, 2026, sold 10,000 shares in Enliven Therapeutics (ELVN) for $504,903. Following the Form 4 filing with the SEC, Kunkel has control over a total of 41,884 common shares of the company, with 41,884 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1672619/000153636826000007/xslF345X05/form4-07082026_090742.xml
$ELVN
Insider Trading
Enliven Therapeutics Insider Sold Shares Worth $263,577, According to a Recent SEC Filing
Benjamin Hohl, CFO, on June 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $263,577. Following the Form 4 filing with the SEC, Hohl has control over a total of 51,000 common shares of the company, with 51,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1672619/000188276426000005/xslF345X05/form4-06222026_090607.xml
$ELVN
Commodities
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) fell 0.3% in Friday's premarket activity, ahead of the debut of Elon Musk's Space Exploration Technologies after markets open.US stock futures were also mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures advancing 0.4%, and Nasdaq futures easing 0.3% before the start of regular trading.The preliminary University of Michigan consumer sentiment report for June will be released at 10 am ET, while the weekly Baker Hughes oil-and-gas rig count posts at 1 pm ET.In premarket action, bitcoin was up by 0.6%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.5% lower, Ether ETF (EETH) retreated 1.5%, and Bitcoin & Ether Market Cap Weight ETF (BETH) lost 0.02%.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.6%, and the iShares US Technology ETF (IYW) was 0.3% lower, while the iShares Expanded Tech Sector ETF (IGM) was up 0.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 0.5%, while the iShares Semiconductor ETF (SOXX) declined by 1.2%.Adobe (ADBE) shares were down more than 9% in premarket activity as multiple analyst price target cuts followed the software maker's latest quarterly results and announcement that Chief Financial Officer Dan Durn had resigned.Winners and Losers:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.7%, and the Vanguard Industrials Index Fund (VIS) was 0.3% higher, while the iShares US Industrials ETF (IYJ) retreated by 0.04%.Rocket Lab (RKLB) stock was up more than 2% before the opening bell after the company said it has been added to the Nasdaq-100 Index, effective June 22.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.1%, the Vanguard Health Care Index Fund (VHT) was down 1%, while the iShares US Healthcare ETF (IYH) gained by 1.6%. The iShares Biotechnology ETF (IBB) was 0.3% higher.Enliven Therapeutics (ELVN) stock was down more than 3% premarket after the company priced an upsized public offering of 8.9 million shares at $37.50 per share and pre-funded warrants to purchase up to 1.73 million shares at $37.499 each.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1.2%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.5% lower.Barclays (BCS) shares were up nearly 2% pre-bell after the British financial services giant agreed to acquire the UK operations of GoHenry, a money-management education platform, from Acorns Grow.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 1.4%. The iShares US Consumer Staples ETF (IYK) retreated by 0.1%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained by 0.1%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.3% higher.Lennar (LEN) shares were down nearly 2% pre-bell after the homebuilder issued a downbeat fiscal Q3 delivery outlook.EnergyThe iShares US Energy ETF (IYE) was down 0.4%, while the State Street Energy Select Sector SPDR ETF (XLE) was 0.5% lower.Venture Global (VG) stock was down more than 1% before market open after the company closed an offering of $1.13 billion of 6.375% senior secured notes due Dec. 15, 2034, and $1.13 billion of 6.625% senior secured notes due June 15, 2036.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 2.7% to $85.37 per barrel on the New York Mercantile Exchange. Natural gas advanced by 0.3% at $3.10 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 1.3%, while the United States Natural Gas Fund (UNG) was 0.4% higher.Gold futures for July advanced by 2.4% to $4,213.40 an ounce on the Comex. Silver futures rose by 4.2% to $66.69 an ounce. SPDR Gold Shares (GLD) was down by 0.3%, and the iShares Silver Trust (SLV) decreased by 0.8%.
Dow JonesNasdaq CompositeS&P 500$ADBE$BCS$BETH$BITO$EEM$EETH$ELVN$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LEN$PMR$QQQ$RKLB$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VG$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Insider Trading
Enliven Therapeutics Insider Sold Shares Worth $345,351, According to a Recent SEC Filing
Lori Anne Kunkel, Director, on June 05, 2026, sold 10,000 shares in Enliven Therapeutics (ELVN) for $345,351. Following the Form 4 filing with the SEC, Kunkel has control over a total of 51,884 common shares of the company, with 51,884 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1672619/000153636826000004/xslF345X05/form4-06092026_080612.xml
$ELVN
Research
Stifel Initiates Enliven Therapeutics at Buy With $60 Price Target
Enliven Therapeutics (ELVN) has an average rating of buy and mean price target of $58.80, according to analysts polled by FactSet.
$ELVN
Research
Guggenheim Initiates Coverage on Enliven Therapeutics With Buy, $80 Price Target
Enliven Therapeutics (ELVN) has an average rating of Buy and mean price target of $56.78, according to analysts polled by FactSet.
$ELVN
